Delta Air Lines (DAL), Consensus 13c. Merit Medical Systems announced that it has reached an agreement in principle with the Department of Justice to fully resolve the DOJ`s previously disclosed investigation into certain marketing and advertising practices. Merit currently expects to contribute $18 million as part of the resolution; The merits, however, deny the allegations. MOVERS ETFs: Includes ETFs and ETNs with a volume of at least 50,000. Sources: FactSet, Alexandra Steiger, an analyst at Dow Jones Goldman Sachs, took over coverage and moved Bumble from Neutral to Buy with a $54 price target of $57 as part of a broader research note on the online dating industry. The company is well positioned to benefit from a number of structural industry tailwinds in the coming years as the online dating landscape remains permeated, the analyst told investors in a research note. However, Steiger adds that while the current valuation is an attractive entry point into a “multi-year composite growth story,” a higher level of “risky” investor behavior may be necessary for better equity performance. Shares of Adagio Therapeutics rose about 23%, or $1.33 per share, to about $7.22 after trading hours on Wednesday after the release of recent results published in three separate publications showing that ADG20, its main mAb monoclonal antibody, has neutralization activity compared to the omicronic variant of SARS-CoV-2 and initiatives to address current and future issues. Variants of SARS-CoV-2. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. Adagio has committed to the U.S. Food and Drug Administration, FDA, regarding potential protocol updates for its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 following the omicron variant.

Goldman Sachs analyst Michael Lapides downgraded CenterPoint Energy`s rating from Buy to Neutral by $30 with a price target of $31. The analyst said the downgrade followed the stock`s relative outperformance in 2021. Lapides added that while he continues to view the company`s EPS growth positively, continued multiple expansion largely depends on consistent implementation over time, as short-term catalysts are limited. Mutual Funds and ETFs: All mutual fund and ETF information contained in this announcement, with the exception of the current price and price history, has been provided by Lipper, A Refinitiv Company, subject to the following provisions: Copyright © Refinitiv. All rights reserved. Any reproduction, republication or redistribution of the lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. LIPPER is not responsible for errors or delays in the content or actions taken based on them. Goldman Sachs analyst Michael Lapides downgraded Evergy from Buy to Neutral with a price target of $72. The analyst said that after a good year of execution, Evergy outperformed in 2021 as the valuation looks slightly less convincing and overhangs in interest rate cases could occur in the first half of 2022. Lapides added that upside potential remains, as a larger investment in renewables than expected could push up estimates. Truist analyst Scot Ciccarelli began reporting on original parts with a sustaining rating and price target of $142. The analyst believes that recent drivers of auto parts, including increased use of personal vehicles, suburban/rural migration and rising vehicle prices, will continue, and believes the company`s industrial distribution business has upside potential.

However, Ciccarelli noted that the company`s weaker/less consistent growth in auto parts keeps it cautious. Brent Thill, an analyst at Jefferies, maintains his hold rating and $120 price target for Elastic, saying that while he remains constructive about the company`s fundamental opportunity, the timing of the management changes announced today just two weeks before the quarter “is worth watching.” Thill adds that with 8 times the expected revenue for 2023, Elastic`s risk-return ratio is balanced given the short-term disruption. Michael Lapides, an analyst at Goldman Sachs, raised WEC Energy from SELL to neutral with a price target of $99. The analyst points to the company`s “significant underperformance of the share price” over the past year, while increasing its expected future earnings multiple by 20 to 22 times. WEC Energy faces a year of falling interest rates in its Wisconsin jurisdictions in 2022, but it sees only modest risk given the historical precedent of fairly favorable payout case procedures, Lapides told investors in a research note. NRx Pharmaceuticals (NRXP) filed a lawsuit against Relief Therapeutics (RLFTF), its former cooperation partner, in the New York State Supreme Court on Monday. The counterclaim describes Relief`s violation and rejection of the collaboration agreement and highlights the false nature of Relief`s claims to have worldwide rights to aviptadil, to have conducted Phase 3 research with aviptadil, and to have all human drugs available to treat patients. The lawsuit describes an earlier pattern of collusion between Raghuram Selvaraju and relief management and staff in cases that led to criminal investigations, sanctions, fines and, in one case, imprisonment. NRx seeks $185 million in fiduciary and other punitive damages related to defamatory and exorbitant conduct. We are confident that the New York State Supreme Court will impose the punishment that this offensive behavior deserves. In fact, we believe that Relief`s conduct is so egregious that it warrants the imposition of punitive damages. According to the law, punitive damages may be awarded if reprehensible and malicious behavior is directed not only against the plaintiff, but also against the public.

NRx intends to donate the punitive damages awarded by the court to help COVID survivors, as they are the true victims of Relief`s actions. The data is provided “as is” for informational purposes only and is not intended for commercial purposes. FactSet (a) makes no warranties, express or implied, of any kind with respect to the Data, including, but not limited to, warranties of merchantability or fitness for a particular purpose; and (b) will not be liable for errors, incompleteness, interruptions or delays, actions taken on the basis of the data, or any damage resulting therefrom. Data may be intentionally delayed according to the provider`s requirements. Adagio Therapeutics summarized the latest findings in three separate publications showing that ADG20, its main monoclonal antibody mAb, has neutralizing activity against the omicronic variant of SARS-CoV-2 and described initiatives to treat current and future variants of SARS-CoV-2. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. Adagio has committed to the U.S. Food and Drug Administration, FDA, regarding potential protocol updates for its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 following the omicron variant.

Recently published in vitro studies investigated the neutralization potentials of large mAb panels against the omicron variant in authentic and pseudovirus tests. The results of the three studies show that among mAbs at the end of clinical development or with emergency use authorization, EUA, ADG20 is one of the few mAbs to have shown neutralizing activity against omicron. Through two different authentic neutralization tests against omicron, the data show that ADG20 had an IC50, a measure of neutralization power, of about 0.4 to 1.1 micrograms/ml, which is comparable to the other two active mAbs, sotrovimab and AZD7742. In addition to clinical trial updates, Adagio is pursuing several strategies to treat both omicron and potential future variants that may arise. Nathan Rich, an analyst at Goldman Sachs, maintains its sell rating and price target of $19 for Covetrus after the company gave a outlook for fiscal 22 during its presentation at the JPMorgan conference today. The adjusted EBITDA guidance of $270 million to $280 million is consistent with comments from the previous quarter calling for double-digit EBITDA growth, exceeding its estimate of $262 million. U.S. dollars, but they are driven by stable expected trade costs, the analyst told investors in a research note, adding that rx management`s revenue growth forecast is more than 20 percent year-on-year. The 22% consensus could be seen as disappointing by investors looking for a stronger recovery. The Q1 sees the average selling price of $472,000.

Fiscal year 22 sees the average selling price of $480,000 – $490,000. Sees gross margin for fiscal year 22 to 26%. Q1 gross profit margin is 22% to -26%. The gross profit margin for fiscal year 22 was 25.4% to 26.2%. Forecasts an effective tax rate of 25% in Q1 and FY22. Says expects the number of communities in Q1 to remain relatively stable. Says expects to end 2022 with 265 municipalities. Says is looking forward to a strong spring sales season. Says expects to end the quarter with net orders in the percentage range at a year-over-year average. Says expects favorable conditions in the housing market to continue. Comments and forecasts from the Q4 earnings conference call.

Goldman Sachs analyst Michael Lapides downgraded Dominion`s rating from Neutral to Sell with a price target of $72. The analyst said the downgrade is largely a relative valuation call, although he also sees potential risks over the next 1-3 years, although those whose timelines are difficult to predict. Our Standards: Thomson Reuters` Principles of Trust. Bonds: Bond quotes are updated in real time. Sources: FactSet, Tullett Prebon * MERIT MEDICAL SYSTEMS INC – FRANKLIN MILLER TO STEP DOWN FROM ITS BOARD OF DIRECTORS NO LATER THAN THE 2020 ANNUAL GENERAL MEETING * MERIT MEDICAL SYSTEMS INC – ANNOUNCES THE FORMATION OF AN OPERATIONS COMMITTEE TO REVIEW MARGIN IMPROVEMENT INITIATIVES AND SET TARGETS Market Journal: U.S. Data. . . .